Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer

Abstract EN

Objective.

In the current study, we measured the expression status of melanoma antigen gene c2 (MAGE-C2) in triple-negative breast cancer (TNBC) and analyzed its prognostic with the clinical pathological features of patients with TNBC.

Methods.

The expressions statuses of MAGE-C2 were detected in TNBC tissues and paracarcinoma tissues by immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR), and western blotting.

Then, we investigated the relationship of MAGE-C2 expression status and clinicopathological parameters of TNBC patients by the chi-squared test.

Finally, we discussed the relations of MAGE-C2 expression state and prognosis of patients with TNBC by Kaplan-Meier method and Cox proportional hazards model.

Results.

High MAGE-C2 expression was found in 38.18% (42/110) of TNBC tissues.

In adjacent tissues it was 9.09% (10/110).

High MAGE-C2 expression in TNBC patients was closely associated with lymph node status, tumor node metastasis (TNM) stage, and lymphovascular invasion (P<0.001).

TNBC patients with high MAGE-C2 expression had significantly shorter survival time than low expression patients.

We also found that age, lymph node status, TNM stage, lymphovascular invasion, and MAGE-C2 expression status were closely associated with overall survival of TNBC patients (P<0.05).

Conclusion.

High MAGE-C2 expression may serve as an independent prognostic factor for TNBC patients.